Roche and Zymeworks Strike $55M Deal on Trispecific Challenger to Amgen’s Imdelltra

Roche is paying Zymeworks $55M upfront for ZW209, a trispecific antibody designed to improve on Amgen’s Imdelltra in small-cell lung cancer.